Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Predictive sciences—built on improved computational capabilities and a deeper understanding of human physiology—are allowing researchers to perform human studies prior to, and sometimes in place of, human clinical trials in order to predict drug outcomes. Representatives of the Translational & ADME Sciences Leadership Group (TALG) in the IQ Consortium review the basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook March 2021 eBook.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook
March 2021
Pages: 24–27
Citation
When referring to this article, please cite it as H. Einolf ,et al., " Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
